Celldex Therapeutics Inc

CLDX

Equity

ISIN US15117B2025 / Valor 46207289

NASDAQ (2024-09-17)

USD 41.24-3.78%

Celldex Therapeutics Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Celldex Therapeutics Inc is a biopharmaceutical company with a focus on developing antibody-based immunotherapies. The company's proprietary antibody programs and technologies are supported by robust in-house capabilities, allowing for the optimized discovery and development of innovative scientific programs. Celldex's lead program, barzolvolimab, is a humanized monoclonal antibody inhibitor of KIT, targeting mast cells involved in severe inflammatory, allergic, and autoimmune diseases. The company aims to provide best-in-class treatment options to improve the lives of patients by targeting core pathological drivers of these diseases.

Summarized from source with an LLMView SourceSector: Technology

Revenue

Celldex Therapeutics Inc. reported total revenue of $2.5 million for the second quarter of 2024, a significant increase compared to $0.3 million in the same quarter of 2023. For the six months ended June 30, 2024, total revenue was $2.7 million, up from $1.2 million in the comparable period of 2023.

Research and Development Expenses

Research and development (R&D) expenses for Celldex Therapeutics Inc. were $39.7 million in the second quarter of 2024, compared to $26.3 million in the second quarter of 2023. For the first half of 2024, R&D expenses totaled $71.3 million, up from $53.0 million in the same period of the previous year.

General and Administrative Expenses

General and administrative (G&A) expenses for Celldex Therapeutics Inc. were $9.1 million in the second quarter of 2024, compared to $7.2 million in the same quarter of 2023. For the six months ended June 30, 2024, G&A expenses were $18.2 million, up from $13.9 million in the comparable period of 2023.

Net Loss

Celldex Therapeutics Inc. reported a net loss of $35.8 million, or ($0.54) per share, for the second quarter of 2024. This compares to a net loss of $30.5 million, or ($0.65) per share, for the second quarter of 2023. For the six months ended June 30, 2024, the net loss was $68.7 million, or ($1.10) per share, compared to $59.9 million, or ($1.27) per share, in the same period of 2023.

Cash Position

As of June 30, 2024, Celldex Therapeutics Inc. had cash, cash equivalents, and marketable securities totaling $802.3 million. This is a substantial increase from $423.6 million as of December 31, 2023, indicating a strong financial position to support ongoing and future operations.

Summarized from source with an LLMView Source

Key figures

47.5%1Y

-24.2%3Y

1,550%5Y

Performance

55.9%1Y

57.3%3Y

76.3%5Y

Volatility